RCKT

Rocket Pharmaceuticals, Inc.

30.45 USD
-0.08 (-0.26%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Rocket Pharmaceuticals, Inc. stock is up 6.65% since 30 days ago. The next earnings date is May 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 9 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
19 Jan 19:33 19 Apr, 2024 30.00 CALL 2000 2464
19 Jan 19:39 19 Apr, 2024 30.00 CALL 250 2464
26 Jan 18:26 19 Jul, 2024 35.00 PUT 46 0
05 Feb 19:18 15 Mar, 2024 25.00 CALL 153 0
09 Feb 15:06 16 Feb, 2024 30.00 CALL 294 1272
16 Feb 15:15 19 Apr, 2024 30.00 CALL 440 4385
21 Feb 15:46 19 Jul, 2024 35.00 PUT 46 46
21 Feb 16:53 15 Mar, 2024 25.00 CALL 153 159
23 Feb 17:59 15 Mar, 2024 30.00 CALL 435 218
27 Feb 16:21 19 Apr, 2024 22.50 CALL 50 410

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells. The company also has a clinical stage in vitro virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure.

  • JP Morgan
    Tue Feb 27, 13:22
    buy
    confirm
  • Cantor Fitzgerald
    Tue Feb 27, 09:30
    buy
    confirm
  • Needham
    Tue Feb 13, 11:45
    buy
    confirm